Birmingham VITTAL Study

The Viability Testing and Transplantation of Marginal Livers (VITTAL) study is due to start recruitment at the Queen Elizabeth Hospital, Birmingham, UK in 2016. It will be led by Professor Darius Mirza and Mr Hynek Mergental. It is designed to determine if a rejected liver is viable using normothermic machine liver perfusion (NMLP). It aims to establish the suitability of livers which have been declined by all UK liver transplant centres by monitoring their function on the OrganOx metra device; and transplant the liver if its function on the machine is satisfactory allowing it to be transplanted.

The clinical trial.gov identifier is NCT02740608
https://clinicaltrials.gov/ct2/show/NCT02740608